United States securities and exchange commission logo





                              June 25, 2020

       James Nathanielsz
       Chief Executive Officer
       Propanc Biopharma, Inc.
       6 Butler Street, Camberwell
       VIC, 3124 Australia

                                                        Re: Propanc Biopharma,
Inc.
                                                            Preliminary
Information Statement on Schedule 14C
                                                            Filed June 11, 2020
                                                            File No. 000-54878

       Dear Mr. Nathanielsz:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Preliminary Information Statement on Schedule 14C

       General

   1.                                                   Please revise your
information statement to ensure consistent disclosures regarding the
                                                        following matters:

                                                            Clarify whether the
range of the reverse stock split is a range of 1-for-1,000, as you
                                                            indicate in your
cover page, or 1-for-500, as you indicate elsewhere in your filing.
                                                            Clarify whether
authorized shares will proportionately decrease with the reverse split
                                                            ratio. If the
number of shares will remain the same or increase, please discuss how
                                                            you will be able to
accomplish the stated purpose of the reverse stock split.
                                                            Clarify how you
will treat fractional shares. In this regard, we note that you state that
                                                            factional shares
will be rounded up, while in other instances you state that cash will
                                                            be delivered in
lieu of fractional shares.
 James Nathanielsz
Propanc Biopharma, Inc.
June 25, 2020
Page 2
              Clarify whether you will increase the number of authorized common
and preferred
              shares as indicated in Exhibit A.
2.       Please revise Exhibit A to clarify the number of authorized preferred
stock. In Article
         4.A, your amendment states that the number of authorized preferred
stock will be
         1,500,005. Article 5.B, however, states that the number of authorized
stock is
         10,000,000.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       You may contact Courtney Lindsay at (202) 551-7237 or Joe McCann at
(202) 551-6262
with any questions.



FirstName LastNameJames Nathanielsz                           Sincerely,
Comapany NamePropanc Biopharma, Inc.
                                                              Division of
Corporation Finance
June 25, 2020 Page 2                                          Office of Life
Sciences
FirstName LastName